What happened with CMPX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Compass Therapeutics is testing cancer treatments designed to act on the immune system and the blood vessels that support tumor growth. Its antibody medicines remain in clinical development; one candidate, tovecimig, targets two signals involved in blood-vessel formation.
The company funds its work mainly by selling shares to investors, rather than selling medicines. It has received a development milestone payment from Elpiscience, which licensed the China rights to tovecimig. The underlying license from ABL Bio requires milestone payments and royalties, and Compass does not hold tovecimig rights in South Korea.
None of its candidates has regulatory approval, so it cannot yet market them. Its path to product revenue depends on successful clinical development and approval, followed by physician and patient acceptance and insurance coverage. It plans either to build its own sales capabilities or work with commercialization partners, and needs additional funding to complete development and bring approved medicines to market.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Compass Therapeutics, Inc.'s prospects hinge on clinical success, especially for tovecimig, licensed from ABL Bio with milestone payments and royalties owed.
Summit Therapeutics competes with Compass through ivonescimab: both it and Compass's CTX-10726 combine PD-1 and VEGF-A blockade in one cancer antibody. Watch ivonescimab's clinical results as a comparison for this approach, not proof that CTX-10726 will work.
Crescent Biopharma, Inc.'s CR-001 directly competes with Compass's CTX-10726; both are clinical-stage cancer antibodies targeting PD-1 and VEGF. Watch CR-001's global Phase 1/2 trial, which began in the first quarter of 2026; Crescent had not yet reported clinical data in cancer patients in the supplied disclosure.
Adagene's ADG206 and ADG106 directly compete with Compass's CTX-471 as experimental cancer antibodies that activate CD137. Follow those two programs rather than treating news about Adagene's lead drug, ADG126, as a direct readout for CTX-471.
BioNTech's pumitamig competes with Compass's CTX-10726 among cancer antibodies that target PD-(L)1 and VEGF together. Pumitamig's development is the relevant comparison for Compass, rather than sales of BioNTech's commercial COVID-19 vaccine, Comirnaty.
Bristol Myers Squibb competes with Compass's checkpoint-directed cancer antibodies through both the drug it sells, Opdivo, and the drug it is developing, pumitamig. Pumitamig's progress is the closer comparison for Compass's CTX-10726 in antibodies targeting PD-(L)1 and VEGF together.
Merck competes with Compass's PD-1-directed cancer antibodies through Keytruda, which it sells, and LM-299, whose development rights it licenses. Watch LM-299's clinical progress for the closer comparison with Compass's PD-1/VEGF-A antibody CTX-10726.
Pfizer competes with Compass's CTX-10726 through SSGJ-707, a cancer antibody it has licensed for development. SSGJ-707's clinical progress is the relevant news to watch in their shared PD-(L)1/VEGF bispecific field, rather than Pfizer's overall medicine sales.
Agenus's PD-1 and CD137 cancer antibodies overlap with Compass's checkpoint and CD137 programs, including CTX-471. Agenus has prioritized botensilimab plus balstilimab (BOT/BAL) and paused some non-core work, so watch which overlapping programs receive funding or partnerships.
Arcus Biosciences, Inc. competes with Compass's immune-directed cancer antibodies by developing checkpoint-based treatment combinations, including zimberelimab and domvanalimab.
Compugen Ltd's cancer checkpoint antibodies compete with Compass's immune-directed antibody programs, including through rilvegostomig, which targets PD-1 and TIGIT. AstraZeneca licenses and develops rilvegostomig and owes Compugen milestone payments and potential royalties, so its development news can come from the partner rather than Compugen itself.
AstraZeneca's marketed cancer drug Imfinzi competes in checkpoint-based treatment with the antibodies Compass is developing. Watch Imfinzi's product sales as evidence of the established treatment market Compass would enter, not as a measure of Compass's clinical success.
Summit Therapeutics Inc. earningsSMMT
Summit Therapeutics' report may provide clinical results for ivonescimab, a direct reference for the PD-1/VEGF-A antibody approach Compass Therapeutics is testing with CTX-10726.
Look for clear anti-cancer activity in ivonescimab's clinical data, and whether the patient group and results support that reading. Convincing evidence would lend early support to combining PD-1 and VEGF-A blockade, but would not establish that CTX-10726 works; limited or unclear results would leave Compass's approach less validated.
Compass Therapeutics, Inc. earningsThis company
Compass Therapeutics has no product-sales revenue and relies on financing to fund clinical development; this report will show whether trial spending remains in step with its cash resources.
Read operating cash use alongside research spending by program and clinical progress. Steady cash use with trials advancing would suggest Compass is pacing development within its resources; faster cash use with limited progress would mean its funds could run down sooner and financing pressure would rise.
